The Prognostic Impact of KRAS

The prognostic impact of KRAS, TP53, STK11 and KEAP1 mutations ...

KRAS mutation was found to be associated with a better median overall survival in STK11 and KEAP1 wild-type tumors (21.1 vs 15.8, p = 0.15).

The Prognostic Impact of KRAS G12C Mutation in Patients ... - PubMed

Among patients with KRAS exon 2 mutated metastatic colorectal cancer (mCRC), median progression-free survival (PFS) and overall survival ...

The prognostic impact of KRAS, TP53, STK11 and KEAP1 mutations ...

The STK11 and KEAP1 mutations are significant adverse predictors of ICI therapy benefit. The NLR is strongly impacted by STK11 mutations but not by KEAP1 ...

The prognostic impact of KRAS, TP53, STK11 and KEAP1 mutations ...

This study shows a trend toward better survival in KRAS mutated NSCLC that harbored wild-type STK11 and KEAP1 genes, which was not seen in STK11 or KEAP1 ...

The Prognostic Impact of KRAS G12C Mutation in Patients with ...

A novel therapy targeting KRAS G12C mutation has demonstrated promising activities for corresponding advanced solid tumors, including metastatic CRC (mCRC).

The Prognostic Impact of KRAS, Its Codon and Amino Acid Specific ...

Particular KRAS codon-specific (codon 13 and 61) and amino acid–specific mutations (G12C or G12V) are associated with differential outcomes compared with other ...

SO-14 The prognostic impact of KRAS G12C mutation in patients ...

The aim of this study was to evaluate the prognostic impact of KRAS G12C mutation in mCRC in a large cohort of real-world data.

Prognostic Impact of KRAS G12C Mutation in Patients With NSCLC

Prognostic impact of KRAS G12C mutation in patients with NSCLC: results from the European Thoracic Oncology Platform Lungscape Project.

Prognostic impact of KRAS mutation status for patients with stage IV ...

Results. 388 (57 %) of 595 patients had a KRAS mutation. KRAS was seen more frequently in women than in men (65 % versus 49 % respectively, p < 0.001). The ...

A retrospective analysis of the prognostic impact of KRAS G12D ...

The KRAS G12D mutation did not show a detrimental prognostic impact on PFS and OS compared to KRAS non-G12D mutations in patients with RAS-mutated mCRC.

The prognostic impact of KRAS, its codon and amino acid specific ...

Multivariate analysis identified KRAS mutation as independent predictor of worse OS (p = 0.001) and DFS (p < 0.0001). CONCLUSION: KRAS is an independent ...

Prognostic impact of mutation profiling in patients with stage II and III ...

KRAS, BRAF and NRAS mutations do not have major prognostic value in stage II and III colon cancer, subtypes of gene mutations should be further investigated.

CMS-dependent prognostic impact of KRAS and BRAF V600E ...

The gene expression–based consensus molecular subtypes (CMSs) of CRC define molecularly and clinically distinct subgroups, and represent a novel stratification ...

The Prognostic Effect of KRAS Mutations in Non-Small Cell Lung ...

Among KRAS mutated, G12C was the most frequent mutation in former/current smokers (45%) and G12D in never smokers (46%). There were no significant differences ...

Assessing the prognostic value of KRAS mutation combined with ...

Conclusions: In our patient cohort, KRAS mutations in combination with primary tumor size did not impact prognosis in stage I-II NSCLC. Introduction. Non-small ...

Abstract 924: The prognostic impact of the KRAS G12C-mutation in ...

Pts with KRAS G12C and WT had similar overall prognosis; however, those with KRAS G12C had worse rwPFS with CT + IO tx, as opposed to a trend in the opposite ...

The Prognostic Impact of KRAS Mutation in Patients Having Curative ...

m-KRAS has been recently reported to be a significant prognostic factor in patients undergoing resection of colorectal liver metastases.

Prognostic and predictive effect of KRAS gene copy number and ...

A small prognostic effect of KRAS mutation was identified for LCSS, and a trend towards worse LCSS, DFS and OS was noted for KRAS MUT + Gain.

Prognostic Effect of BRAF and KRAS Mutations in Patients With ...

Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.

Prognostic impact of KRAS mutation status for patients with stage IV ...

Conclusion: The survival of KRAS mutated versus KRAS wild-type lung adenocarcinoma patients, treated with first-line pembrolizumab monotherapy, ...